PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Kolb, H.J. ; Schmid, C.*

The FLAMSA concept-past and future.

Ann. Hematol. 99, 1979–1988 (2020)
Verlagsversion DOI PMC
Closed
The FLAMSA reduced intensity (RIC) concept, also known as "sequential therapy", is a conceptual platform for the treatment of leukemia separated in several parts: induction therapy, a sequence of antileukemic and immunosuppressive conditioning for allogeneic stem cell transplantation, and immune restitution supported by donor lymphocyte transfusions. The antileukemic part consists of fludarabine, cytosine arabinoside, and amsacrine (FLAMSA); non-cross reactive agents like fludarabine and amsacrine have been successfully used in cases of refractoriness and relapse. Immunosuppressive conditioning and transplantation follow after only 3 days of rest. This way, the toxicity of allogeneic transplantation could be reduced and the anti-leukemia effects by using allogeneic immune cells could be optimized. This review summarizes available data on efficacy and toxicity of this approach. Further, possible strategies for improvements are discussed in order to provide better chances for elderly and frail patients and patients with advanced and high-risk disease. Among others, several new agents are available that target molecular changes of leukemia for induction of remission and allow for bridging the time after transplantation until adoptive immunotherapy becomes safe and effective.
Impact Factor
Scopus SNIP
Altmetric
2.904
0.934
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Aml ; Mds ; Transplantation ; Conditioning ; Flamsa ; Dli ; Graft Versus Leukemia ; Targeted Therapy; Acute Myeloid-leukemia; Stem-cell Transplantation; Versus-host-disease; Bone-marrow-transplantation; Chronic Myelogenous Leukemia; Donor Lymphocyte Infusions; Minimal Residual Disease; Acute Nonlymphocytic Leukemia; Low-dose Cytarabine; Adoptive Immunotherapy
Sprache englisch
Veröffentlichungsjahr 2020
HGF-Berichtsjahr 2020
ISSN (print) / ISBN 0939-5555
e-ISSN 1432-0584
Zeitschrift Annals of Hematology
Quellenangaben Band: 99, Heft: , Seiten: 1979–1988 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort One New York Plaza, Suite 4600, New York, Ny, United States
Begutachtungsstatus Peer reviewed
Institut(e) CCG Immunotherapy (KKG-KIT)
POF Topic(s) 30504 - Mechanisms of Genetic and Environmental Influences on Health and Disease
Forschungsfeld(er) Immune Response and Infection
PSP-Element(e) G-520360-001
DOI 10.1007/s00277-020-04131-1
WOS ID WOS:000543687800002
Scopus ID 85086908756
PubMed ID 32594216
Erfassungsdatum 2020-07-08
[➜Korrektur melden]